These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30341384)

  • 41. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
    Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
    J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha.
    Jani V; Sonavane U; Sawant S
    Comput Biol Chem; 2024 Feb; 108():107994. PubMed ID: 38043374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
    Ni D; Liu D; Zhang J; Lu S
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precision Targeting of Mutant PI3Kα.
    Gong GQ; Vanhaesebroeck B
    Cancer Discov; 2024 Feb; 14(2):204-207. PubMed ID: 38327193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
    Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
    J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the
    Jiang W; Wu Y; He T; Zhu H; Ke G; Xiang L; Yang H
    Mol Cancer Ther; 2020 Feb; 19(2):337-347. PubMed ID: 31666350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase.
    Tyukhtenko S; Rajarshi G; Karageorgos I; Zvonok N; Gallagher ES; Huang H; Vemuri K; Hudgens JW; Ma X; Nasr ML; Pavlopoulos S; Makriyannis A
    Sci Rep; 2018 Jan; 8(1):1719. PubMed ID: 29379013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors.
    Lu Y; Knapp M; Crawford K; Warne R; Elling R; Yan K; Doyle M; Pardee G; Zhang L; Ma S; Mamo M; Ornelas E; Pan Y; Bussiere D; Jansen J; Zaror I; Lai A; Barsanti P; Sim J
    J Mol Biol; 2017 Jun; 429(11):1684-1704. PubMed ID: 28433539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
    Chaussade C; Cho K; Mawson C; Rewcastle GW; Shepherd PR
    Biochem Biophys Res Commun; 2009 Apr; 381(4):577-81. PubMed ID: 19233141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Probing the dynamic regulation of peripheral membrane proteins using hydrogen deuterium exchange-MS (HDX-MS).
    Vadas O; Burke JE
    Biochem Soc Trans; 2015 Oct; 43(5):773-86. PubMed ID: 26517882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
    Buckbinder L; St Jean DJ; Tieu T; Ladd B; Hilbert B; Wang W; Alltucker JT; Manimala S; Kryukov GV; Brooijmans N; Dowdell G; Jonsson P; Huff M; Guzman-Perez A; Jackson EL; Goncalves MD; Stuart DD
    Cancer Discov; 2023 Nov; 13(11):2432-2447. PubMed ID: 37623743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.
    Hart JR; Liu X; Pan C; Liang A; Ueno L; Xu Y; Quezada A; Zou X; Yang S; Zhou Q; Schoonooghe S; Hassanzadeh-Ghassabeh G; Xia T; Shui W; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2210769119. PubMed ID: 36095215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).
    Vogt PK; Hart JR; Yang S; Zhou Q; Yang D; Wang MW
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188947. PubMed ID: 37394020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational study of the W260A activating mutant of Src tyrosine kinase.
    Meng Y; Roux B
    Protein Sci; 2016 Jan; 25(1):219-30. PubMed ID: 26106037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.
    Meyer DS; Koren S; Leroy C; Brinkhaus H; Müller U; Klebba I; Müller M; Cardiff RD; Bentires-Alj M
    Oncogenesis; 2013 Sep; 2(9):e74. PubMed ID: 24080956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.